|
1.4 BIOLOGIE - TECHNOS, MODÈLES
|
|
|
|
4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
|
|
|
|
4.1 DÉP., DIAG. & PRONO. - PROSTATE
|
|
|
|
4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS
|
|
|
|
|
4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
WuXi upgrades CAR-T offerings with new manufacturing platform [Fierce Pharma]
|
|
|
|
|
|
CAR-T is a particularly hot field in the oncology arena, as last week’s abstract release for the upcoming American Society of Clinical Oncology virtual annual meeting exemplified. But when it comes to taking drugs from development to market, drugmakers so far have stumbled on account of the complex manufacturing processes required to reprogram patients’ cells.
|
|
|
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
|
5.12.7 IMMUNOTHÉRAPIES - VACCINS
|
|
|
|
5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
|
|
|
|
5.2 PHARMA
|
|
|
|
5.2.6 PHARMA - BIOTECH
|
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
|
5.5.1.1 ASCO (GÉNÉRAL) - INDUSTRIELS
|
|
|
|
5.5.17 ASCO (PANCRÉAS)
|
|
|
|
5.6.6 ESMO - SEIN
|
|
|
|
|
|
5.9.3 EHA
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|
|
|
6.1 OBSERVATION
|
|
|
|
6.15 LUTTE CONTRE LES CANCERS - COVID-19
|
|
|
|
|
6.6 PUBLICATIONS, POLITIQUES SCIENTIFIQUES
|
|
|